RussianPatents.com

Use of modified cyclosporines. RU patent 2463071.

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

EFFECT: group of inventions provides directed action on the elimination of adverse stimuli in liver transplantation.

3 cl

IPC classes for russian patent Use of modified cyclosporines. RU patent 2463071. (RU 2463071):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K38/13 - Cyclosporins

Another patents in same IPC classes:

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.

Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress / 2455970
Invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.

Nonimmunosuppressive cyclosporine for treating congenital ullrich myopathy / 2462262
Invention refers to medicine and concerns the use of a non-immunosuppressive derivative of cyclosporine A for reducing mitochondrial dysfunction and a degree of apoptosis in patient's cells with diagnosed congenital Ullrich myopathy or Bethlem myopathy.

Kit for parenteral drug introduction / 2446828
Invention refers to pharmaceutical industry, particularly a kit for parenteral tacrolimus introduction. The kit comprises: a bottle 5 to 10 ml containing anhydrous tacrolimus 5 mg dissolved in lipophilic solvent 1 ml; a container containing a liquid for parenteral introduction specified in normal saline or glucose solution; a means for drug delivery from the bottle to the container. The container, the bottle and the means for drug delivery are made of materials specified in glass, polyethylene polypropylene and phthalate-free PVC.

Prolongation of allograft survival by complement activity inhibition / 2445975
Group of inventions refers to medicine, namely to transplantology, and can be used for prolongation of allotransplantated cell, tissue and organ survival. A method under the invention refers to introducing a drug preparation which inhibits a complement, IL-2 and LF15-0195 inhibitor activity. Also, the group of inventions refers to applying the drug preparation which inhibits the complement, IL-2 and LF15-0195 inhibitor activity for producing the drug preparation and the pharmaceutical kit.

Methods and pharmaceutical compositions for treatment and prevention of hepatitis c infection / 2440822
Group of inventions relates to medicine, namely to virology, hepatology, and can be used for treatment or prevention of viral hepatitis C infection. For this purpose therapeutically efficient amount of 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucin) cyclosporine or its pharmaceutically acceptable salt or solvate in combination with therapeutically efficient amount of second preparation is introduced to patient. Second preparation is selected from modulators of protease NS3-4A, nucleoside modulators RNA-dependent RNA-polymerase NS5B, non-nucleoside modulators RNA-dependent RNA-polymerase NS5B, riboflavin and immunomodulating medications. Also claimed are pharmaceutical compositions and sets.

Novel cyclic peptide compounds / 2436795
Invention relates to a novel cyclic peptide compound of pharmaceutically acceptable salt thereof, having activity against hepatitis C virus, based on inhibiting activity against replication of the hepatitis C virus RNA replicon, a pharmaceutical composition containing said compound or pharmaceutically acceptable salt thereof, and use of the compounds or pharmaceutically acceptable salt thereof to prepare a medicinal agent with anti-HCV activity.

Pharmaceutical compositions for treating dry eye syndrome / 2431502
Invention refers to pharmaceutics and medicine, and concerns a composition for treating or relieving dry eye syndrome containing a dissociated glucocorticoid receptor agonist ("DIGRA") of formula , a method of producing, a method of treating dry eye syndrome and applying a compound of formula IV for preparing the composition for treating dry eye syndrome.

New cyclic peptide compounds / 2423377
Present invention refers to a new cyclic peptide compound or its pharmaceutically acceptable salt which shows a hepatitis C virus activity based on an inhibiting activity of RNA replication of a hepatitis C virus replicon, to a method of producing it involving regrouping in a soft acid medium followed by amino acid exchange reactions, to a pharmaceutical composition containing said compound.

Pharmaceutical compositions containing cyclosporine / 2421209
Invention refers to pharmaceutical industry. A liquid pharmaceutical composition containing cyclosporine, an aqueous liquid carrier, a first solubility-enabling substance selected from a group of phospholipids and a second solubility-enabling substance selected from a group of non-ionic surface-active substances, and a phospholipid represents a mixture of natural phospholipids and contains cyclosporine in a liposomally solubilised form. A method of producing the composition. Application of the composition. A container containing the composition. A method of filling the container with the composition. Method of producing an aerosol.

Methods for increasing biological availability of renin inhibitor / 2404758
Invention relates to medicinal agents and method for increasing biological availability of renin inhibitor, consisting in the fact that to mammal in need of such treatment, combination containing renin inhibitor and exhaustive protein inhibitor is jointly administered, in which inhibitor of exhaustive protein represents inhibitor MDR1, such as PSC833, and renin inhibitor represents derivative of amide δ-amino-γ-hydroxy-ω-arylalkanoic acid, with formula of (I), where R1, R2, R3 and R4 have values specified in the formula.

Cyclosporin derivatives, substituted with 3-ether and 3-thioether for treating and preventing infectious hepatitis c / 2399628
In cyclosporine derivatives of general formula A, B, R1, R2 and X are defined in the description, for use in treating viral hepatitis C.

Cyclosporin-containing and practically oil-free compositions / 2249461
The present innovation deals with cyclosporin-containing and practically oil-free compositions being of immunosuppressive action. The composition contains a hydrophilic surface-active substance, a lipophilic component, a lipophilic surface-active substance and ethanol. As a hydrophilic surface-active substance this composition contains ether of fatty acid and polyoxyethylene sorbitane and product of either natural or hydrogenised castor oil and ethylenoxide; as a lipophilic component and lipophilic surface-active substance it contains ether of fatty acid and sorbitane. The suggested composition has been designed as a gelatinous capsule with solid covering. The present innovation solves the problem dealing with stability of galena compositions with cyclosporin: at treating with water the composition develops practically stable microemulsion.